[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-001", "question": "A 45-year-old man with a history of alcoholic cirrhosis presents to the ICU with massive upper gastrointestinal bleeding. Despite endoscopic intervention and octreotide infusion, bleeding persists, and he develops hemodynamic instability. Transjugular intrahepatic portosystemic shunt (TIPS) is considered, but imaging reveals a rare anatomical variant. What is the most appropriate next step in management?", "options": ["Proceed with TIPS using a covered stent to mitigate risks", "Initiate balloon tamponade with a Sengstaken-Blakemore tube", "Administer terlipressin as an alternative vasoconstrictor", "Perform urgent surgical portocaval shunt", "Refer for angiographic embolization of the coronary vein"], "answer": "E", "answer_index": 4, "explanation": "In persistent variceal bleeding with anatomical variants precluding TIPS, angiographic embolization targets specific bleeding vessels like the coronary vein, offering a less invasive option. TIPS is contraindicated due to the variant, while surgical shunts carry high mortality in unstable patients. Terlipressin and balloon tamponade are temporizing but not definitive here.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible) leading to potential K (Miskeyed).\\n\\nVerdict on keyed answer: The keyed answer (E) is medically controversial as the 'next step' and potentially inferior to Option B.\\n\\nReasoning: The patient is hemodynamically unstable with massive bleeding refractory to endoscopy. The standard of care in this immediate life-threatening scenario is to establish temporary control to prevent exsanguination. Balloon tamponade (Option B) is the specific guideline-recommended 'bridge' therapy for unstable patients while definitive therapy is arranged. While the author excludes B as 'temporizing,' medical priority dictates stabilization first. Furthermore, transvenous embolization (Option E) without TIPS is not the universal standard of care for esophageal varices (high rebleed rate) compared to surgical shunts or transplant evaluation, though it is a valid salvage option. The vague 'rare anatomical variant' is an underspecified plot device used to disqualify TIPS but does not clarify why embolization is superior to immediate tamponade or surgery. Consequently, Option B is defensible as the immediate safety step, while Option E is the intended definitive step, creating a 'bridge vs. destination' logical conflict.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible) leading to potential K (Miskeyed).\n\nVerdict on keyed answer: The keyed answer (E) is medically controversial as the 'next step' and potentially inferior to Option B.\n\nReasoning: The patient is hemodynamically unstable with massive bleeding refractory to endoscopy. The standard of care in this immediate life-threatening scenario is to establish temporary control to prevent exsanguination. Balloon tamponade (Option B) is the specific guideline-recommended 'bridge' therapy for unstable patients while definitive therapy is arranged. While the author excludes B as 'temporizing,' medical priority dictates stabilization first. Furthermore, transvenous embolization (Option E) without TIPS is not the universal standard of care for esophageal varices (high rebleed rate) compared to surgical shunts or transplant evaluation, though it is a valid salvage option. The vague 'rare anatomical variant' is an underspecified plot device used to disqualify TIPS but does not clarify why embolization is superior to immediate tamponade or surgery. Consequently, Option B is defensible as the immediate safety step, while Option E is the intended definitive step, creating a 'bridge vs. destination' logical conflict.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-002", "question": "A 62-year-old woman with metastatic breast cancer on paclitaxel develops acute dyspnea and hypoxemia. CT angiography shows no pulmonary embolism, but echocardiography reveals right ventricular strain. Bone marrow biopsy confirms tumor infiltration. What is the most likely diagnosis?", "options": ["Paclitaxel-induced pneumonitis", "Tumor microembolism syndrome", "Lymphangitic carcinomatosis", "Chemotherapy-associated pulmonary veno-occlusive disease", "Metastatic tumor thrombus in pulmonary arteries"], "answer": "B", "answer_index": 1, "explanation": "Tumor microembolism syndrome occurs when tumor cells embolize to pulmonary vasculature, causing right heart strain without macroscopic emboli, fitting this presentation in metastatic cancer. Lymphangitic carcinomatosis typically shows interstitial patterns on imaging, while paclitaxel pneumonitis is inflammatory. Veno-occlusive disease is more associated with stem cell transplant regimens.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item describes a classic presentation of Pulmonary Tumor Thrombotic Microangiopathy (PTTM), often referred to as tumor microembolism syndrome. The key clinical features driving the diagnosis are: 1) Metastatic carcinoma (breast cancer is a known cause), 2) Signs of acute/subacute pulmonary hypertension and right heart failure (RV strain), and 3) A CT angiogram negative for macroscopic pulmonary embolism. This specific combination—severe pulmonary hypertension/RV strain with no visible clot on CTA—is the hallmark of microscopic tumor emboli occluding small pulmonary arterioles. Option A (Pneumonitis) and C (Lymphangitic carcinomatosis) would typically present with distinct parenchymal findings (ground-glass opacities, septal thickening) on the CT scan, which are not mentioned, and the negative CTA focuses the differential on vascular occlusion. Option E (Metastatic tumor thrombus) implies macroscopic emboli, which would be visible as filling defects on CTA. The item is medically accurate and logically sound, using standard board-exam discriminators.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item describes a classic presentation of Pulmonary Tumor Thrombotic Microangiopathy (PTTM), often referred to as tumor microembolism syndrome. The key clinical features driving the diagnosis are: 1) Metastatic carcinoma (breast cancer is a known cause), 2) Signs of acute/subacute pulmonary hypertension and right heart failure (RV strain), and 3) A CT angiogram negative for macroscopic pulmonary embolism. This specific combination—severe pulmonary hypertension/RV strain with no visible clot on CTA—is the hallmark of microscopic tumor emboli occluding small pulmonary arterioles. Option A (Pneumonitis) and C (Lymphangitic carcinomatosis) would typically present with distinct parenchymal findings (ground-glass opacities, septal thickening) on the CT scan, which are not mentioned, and the negative CTA focuses the differential on vascular occlusion. Option E (Metastatic tumor thrombus) implies macroscopic emboli, which would be visible as filling defects on CTA. The item is medically accurate and logically sound, using standard board-exam discriminators.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-003", "question": "A 28-year-old man presents to the emergency department with severe headache, vomiting, and photophobia after a recent hiking trip. CSF analysis shows lymphocytic pleocytosis, elevated protein, and normal glucose. PCR for common viruses is negative, but serology reveals antibodies to a rare pathogen. What is the most appropriate initial management?", "options": ["Intravenous acyclovir for presumed herpes encephalitis", "Empiric antibiotics for bacterial meningitis", "Supportive care with close monitoring", "Corticosteroids to reduce inflammation", "Antifungal therapy targeting endemic mycoses"], "answer": "C", "answer_index": 2, "explanation": "This presentation suggests lymphocytic meningitis from a rare arbovirus like Jamestown Canyon virus, where supportive care is the mainstay as no specific antiviral exists. Acyclovir is for herpes, unnecessary here with negative PCR. Antibiotics are for bacterial etiologies, ruled out by CSF profile.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item is logically invalid due to critical underspecification. The stem states that serology revealed antibodies to a \\\"rare pathogen\\\" but fails to identify the specific organism. The correct management depends entirely on the etiology of this pathogen. While the provided rationale assumes an arbovirus (like Jamestown Canyon virus) which requires supportive care (Option C), the description \\\"rare pathogen\\\" acquired during hiking could equally apply to treatable etiologies such as fungal infections (e.g., Coccidioidomycosis) or spirochetal diseases (e.g., Lyme disease), which would require antifungals (Option E) or antibiotics, respectively. The CSF profile (lymphocytic pleocytosis, normal glucose) is consistent with viral, fungal, or spirochetal meningitis. Without naming the pathogen, it is impossible to distinguish between a self-limiting condition requiring supportive care and a serious infection requiring specific antimicrobial therapy. To fix this, the stem must explicitly name the pathogen identified by serology (e.g., \\\"antibodies to Jamestown Canyon virus\\\").\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item is logically invalid due to critical underspecification. The stem states that serology revealed antibodies to a \"rare pathogen\" but fails to identify the specific organism. The correct management depends entirely on the etiology of this pathogen. While the provided rationale assumes an arbovirus (like Jamestown Canyon virus) which requires supportive care (Option C), the description \"rare pathogen\" acquired during hiking could equally apply to treatable etiologies such as fungal infections (e.g., Coccidioidomycosis) or spirochetal diseases (e.g., Lyme disease), which would require antifungals (Option E) or antibiotics, respectively. The CSF profile (lymphocytic pleocytosis, normal glucose) is consistent with viral, fungal, or spirochetal meningitis. Without naming the pathogen, it is impossible to distinguish between a self-limiting condition requiring supportive care and a serious infection requiring specific antimicrobial therapy. To fix this, the stem must explicitly name the pathogen identified by serology (e.g., \"antibodies to Jamestown Canyon virus\").", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-004", "question": "A 7-year-old boy with autism spectrum disorder presents with recurrent episodes of staring spells and facial twitching. EEG shows multifocal epileptiform discharges, and MRI reveals subtle cortical dysplasia. Genetic testing identifies a de novo mutation. What is the most effective first-line therapy?", "options": ["Valproic acid for broad-spectrum coverage", "Levetiracetam to minimize behavioral side effects", "Carbamazepine for focal seizures", "Vagus nerve stimulation as adjunct", "Ketogenic diet initiation"], "answer": "B", "answer_index": 1, "explanation": "In epileptic encephalopathy due to mutations like SCN8A, levetiracetam is preferred for its efficacy and lower risk of exacerbating behavioral issues in autism. Valproic acid can worsen aggression, while carbamazepine may aggravate generalized features. Dietary therapies are second-line.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: Underspecified (U) and Medically Inaccurate. \\nVerdict: No defensible answer. \\n\\nThe item is logically flawed because the stem mentions 'a de novo mutation' without specifying the gene, yet the rationale relies entirely on the mutation being 'SCN8A' to justify the answer. Without naming the gene, the clinical picture (cortical dysplasia, multifocal EEG, focal/generalized features) allows for multiple first-line options (Valproic acid, Levetiracetam, or Carbamazepine), making the item unsolvable (Underspecified). \\n\\nCritically, the medical reasoning provided for the key (Levetiracetam) is factually incorrect. The rationale claims Levetiracetam is chosen to 'minimize behavioral side effects' in a child with autism. In standard practice, Levetiracetam is associated with a high risk of irritability, aggression, and behavioral changes ('Keppra rage'), particularly in children with baseline behavioral disorders like ASD. Many neurologists would avoid Levetiracetam or use it with extreme caution in this patient profile, contradicting the item's central teaching point. \\n\\nMinimal fix: Specify the mutation (e.g., 'SCN8A') in the stem and correct the rationale regarding side effects (or change the patient's comorbidity to avoid the Levetiracetam/behavior contradiction).\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: Underspecified (U) and Medically Inaccurate. \nVerdict: No defensible answer. \n\nThe item is logically flawed because the stem mentions 'a de novo mutation' without specifying the gene, yet the rationale relies entirely on the mutation being 'SCN8A' to justify the answer. Without naming the gene, the clinical picture (cortical dysplasia, multifocal EEG, focal/generalized features) allows for multiple first-line options (Valproic acid, Levetiracetam, or Carbamazepine), making the item unsolvable (Underspecified). \n\nCritically, the medical reasoning provided for the key (Levetiracetam) is factually incorrect. The rationale claims Levetiracetam is chosen to 'minimize behavioral side effects' in a child with autism. In standard practice, Levetiracetam is associated with a high risk of irritability, aggression, and behavioral changes ('Keppra rage'), particularly in children with baseline behavioral disorders like ASD. Many neurologists would avoid Levetiracetam or use it with extreme caution in this patient profile, contradicting the item's central teaching point. \n\nMinimal fix: Specify the mutation (e.g., 'SCN8A') in the stem and correct the rationale regarding side effects (or change the patient's comorbidity to avoid the Levetiracetam/behavior contradiction).", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-005", "question": "A 55-year-old man with Parkinson's disease develops sudden onset of dysarthria and hemiparesis. MRI shows acute infarction in the lenticulostriate territory, but vessel imaging is normal. Coagulation studies reveal an abnormality. What is the underlying mechanism?", "options": ["Cardioembolic stroke from atrial fibrillation", "Lacunar infarct due to small vessel disease", "Thrombotic stroke from antiphospholipid syndrome", "Vasculitis mimicking stroke", "Embolic stroke from levodopa-induced arrhythmia"], "answer": "C", "answer_index": 2, "explanation": "Antiphospholipid syndrome can cause thrombotic strokes in atypical territories without large vessel occlusion, especially with coagulation abnormalities. Lacunar infarcts are typically hypertensive, not matching this profile. Cardioembolism usually involves larger territories or arrhythmias, absent here.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item describes a patient with a lenticulostriate infarction, which is anatomically a lacunar stroke. Epidemiologically, the vast majority of these are caused by small vessel disease (lipohyalinosis) related to hypertension (Option B). However, the stem introduces a specific discriminator: \\\"Coagulation studies reveal an abnormality.\\\" In the context of board examinations, this clue is intended to rule out standard small vessel disease and point toward a hypercoagulable state. Among the choices, only Antiphospholipid Syndrome (Option C) is a primary thrombophilia that would manifest with a coagulation abnormality (classically a prolonged PTT due to the lupus anticoagulant) and cause thrombosis. While the phrasing \\\"reveal an abnormality\\\" is somewhat underspecified (it does not specify PTT vs. other values), Option C is the only choice mechanistically linked to a coagulation defect. Options A and E are embolic and unrelated to coagulopathy; Option D (vasculitis) is inflammatory. Therefore, despite the strong epidemiological pull of Option B, the specific lab finding makes C the unique best answer under exam logic.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item describes a patient with a lenticulostriate infarction, which is anatomically a lacunar stroke. Epidemiologically, the vast majority of these are caused by small vessel disease (lipohyalinosis) related to hypertension (Option B). However, the stem introduces a specific discriminator: \"Coagulation studies reveal an abnormality.\" In the context of board examinations, this clue is intended to rule out standard small vessel disease and point toward a hypercoagulable state. Among the choices, only Antiphospholipid Syndrome (Option C) is a primary thrombophilia that would manifest with a coagulation abnormality (classically a prolonged PTT due to the lupus anticoagulant) and cause thrombosis. While the phrasing \"reveal an abnormality\" is somewhat underspecified (it does not specify PTT vs. other values), Option C is the only choice mechanistically linked to a coagulation defect. Options A and E are embolic and unrelated to coagulopathy; Option D (vasculitis) is inflammatory. Therefore, despite the strong epidemiological pull of Option B, the specific lab finding makes C the unique best answer under exam logic.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-006", "question": "In the ICU, a 70-year-old patient with septic shock from pneumonia remains hypotensive despite vasopressors and fluids. Adrenal function testing shows a blunted cortisol response, but random cortisol is normal. What is the next step in management?", "options": ["Initiate hydrocortisone replacement therapy", "Add fludrocortisone for mineralocorticoid support", "Perform cosyntropin stimulation test", "Switch to alternative vasopressor like vasopressin", "Administer ascorbic acid and thiamine"], "answer": "D", "answer_index": 3, "explanation": "Relative adrenal insufficiency in sepsis may not respond to steroids if cortisol is normal; switching to vasopressin addresses vasoplegia more effectively. Hydrocortisone is controversial without clear deficiency. Cosyntropin is already implied by blunted response.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a patient with septic shock who remains hypotensive despite fluid and vasopressor resuscitation (refractory shock). The specific inclusion of 'blunted cortisol response' is a decisive board-exam clue indicating Critical Illness-Related Corticosteroid Insufficiency (CIRCI). According to Surviving Sepsis Campaign guidelines, patients with septic shock refractory to vasopressors should receive IV hydrocortisone (Option A). The provided key (D) is medically and logically flawed for two reasons: first, vasopressin is typically 'added' to norepinephrine as a second-line agent, not 'switched' (which implies discontinuing the first pressor, a dangerous move in instability); second, the rationale ignores the explicit diagnostic clue (blunted response) that justifies steroids. While the utility of ACTH testing is debated, providing a 'blunted' result in a question stem creates a logical mandate to treat the insufficiency. Therefore, Option A is the supported best answer, and the item is miskeyed.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a patient with septic shock who remains hypotensive despite fluid and vasopressor resuscitation (refractory shock). The specific inclusion of 'blunted cortisol response' is a decisive board-exam clue indicating Critical Illness-Related Corticosteroid Insufficiency (CIRCI). According to Surviving Sepsis Campaign guidelines, patients with septic shock refractory to vasopressors should receive IV hydrocortisone (Option A). The provided key (D) is medically and logically flawed for two reasons: first, vasopressin is typically 'added' to norepinephrine as a second-line agent, not 'switched' (which implies discontinuing the first pressor, a dangerous move in instability); second, the rationale ignores the explicit diagnostic clue (blunted response) that justifies steroids. While the utility of ACTH testing is debated, providing a 'blunted' result in a question stem creates a logical mandate to treat the insufficiency. Therefore, Option A is the supported best answer, and the item is miskeyed.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-007", "question": "A 38-year-old woman with chronic myeloid leukemia on dasatinib develops pleural effusions and fatigue. Cytogenetic analysis shows additional clonal evolution. What is the most appropriate therapeutic adjustment?", "options": ["Switch to imatinib to reduce pulmonary toxicity", "Add interferon-alpha for immunomodulation", "Initiate ponatinib for resistant mutations", "Dose reduce dasatinib and monitor", "Proceed to allogeneic stem cell transplant"], "answer": "C", "answer_index": 2, "explanation": "Clonal evolution in CML on dasatinib often indicates T315I mutation, for which ponatinib is effective despite pulmonary risks. Imatinib lacks potency against advanced disease. Transplant is considered but not first-line without failure of second-generation TKIs.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with CML failing second-generation TKI therapy (dasatinib), evidenced by 'additional clonal evolution' (a marker of disease progression/resistance) and significant toxicity (pleural effusions). The most appropriate management for disease progression on a second-generation TKI is to switch to a more potent TKI or evaluate for allogeneic transplant. Among the options, Ponatinib (C) is the only TKI listed with efficacy against resistant disease (including T315I mutations) and is the standard pharmacologic next step to regain control, often as a bridge to transplant. Option A is a step backward in potency. Option D is unsafe as it ignores disease progression. Option E (Transplant) is a valid long-term strategy for a young patient with clonal evolution, but 'proceed to' implies an immediate action; standard practice requires disease control with salvage therapy (like Ponatinib) first. Therefore, C is the single best answer. Note: The provided rationale inaccurately conflates 'clonal evolution' (chromosomal abnormalities) with 'T315I mutation' (a gene mutation). While both drive resistance, they are distinct entities. This medical imprecision in the rationale does not invalidate the correct key but lowers the accuracy score.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with CML failing second-generation TKI therapy (dasatinib), evidenced by 'additional clonal evolution' (a marker of disease progression/resistance) and significant toxicity (pleural effusions). The most appropriate management for disease progression on a second-generation TKI is to switch to a more potent TKI or evaluate for allogeneic transplant. Among the options, Ponatinib (C) is the only TKI listed with efficacy against resistant disease (including T315I mutations) and is the standard pharmacologic next step to regain control, often as a bridge to transplant. Option A is a step backward in potency. Option D is unsafe as it ignores disease progression. Option E (Transplant) is a valid long-term strategy for a young patient with clonal evolution, but 'proceed to' implies an immediate action; standard practice requires disease control with salvage therapy (like Ponatinib) first. Therefore, C is the single best answer. Note: The provided rationale inaccurately conflates 'clonal evolution' (chromosomal abnormalities) with 'T315I mutation' (a gene mutation). While both drive resistance, they are distinct entities. This medical imprecision in the rationale does not invalidate the correct key but lowers the accuracy score.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-008", "question": "A 35-year-old woman in the emergency department collapses after ingesting an unknown substance. She has bradycardia, hypotension, and miosis. Atropine provides partial response, but symptoms recur. What is the definitive antidote?", "options": ["Pralidoxime for organophosphate poisoning", "N-acetylcysteine for acetaminophen", "Flumazenil for benzodiazepine overdose", "Physostigmine for anticholinergic toxicity", "Hydroxocobalamin for cyanide"], "answer": "A", "answer_index": 0, "explanation": "This cholinergic toxidrome suggests organophosphate poisoning, where pralidoxime regenerates acetylcholinesterase after initial atropine. Atropine alone is insufficient for severe cases. Other antidotes target different mechanisms not fitting the presentation.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a classic cholinergic toxidrome characterized by miosis, bradycardia, and hypotension. This constellation of symptoms strongly suggests organophosphate or carbamate poisoning. The partial response to atropine (a muscarinic antagonist) confirms the involvement of excess acetylcholine at muscarinic receptors; however, atropine does not reverse the underlying acetylcholinesterase inhibition or nicotinic effects (such as neuromuscular blockade). Pralidoxime (Option A) is the definitive antidote for organophosphate poisoning as it regenerates acetylcholinesterase, addressing the root cause. Option D (Physostigmine) is an acetylcholinesterase inhibitor used for anticholinergic toxicity; administering it here would exacerbate the cholinergic crisis and is contraindicated. Options B, C, and E treat acetaminophen, benzodiazepine, and cyanide toxicity, respectively, none of which match the clinical presentation. The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a classic cholinergic toxidrome characterized by miosis, bradycardia, and hypotension. This constellation of symptoms strongly suggests organophosphate or carbamate poisoning. The partial response to atropine (a muscarinic antagonist) confirms the involvement of excess acetylcholine at muscarinic receptors; however, atropine does not reverse the underlying acetylcholinesterase inhibition or nicotinic effects (such as neuromuscular blockade). Pralidoxime (Option A) is the definitive antidote for organophosphate poisoning as it regenerates acetylcholinesterase, addressing the root cause. Option D (Physostigmine) is an acetylcholinesterase inhibitor used for anticholinergic toxicity; administering it here would exacerbate the cholinergic crisis and is contraindicated. Options B, C, and E treat acetaminophen, benzodiazepine, and cyanide toxicity, respectively, none of which match the clinical presentation. The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-009", "question": "A 12-year-old girl with juvenile idiopathic arthritis on etanercept develops fever, rash, and lymphadenopathy. Serology is positive for a virus, but PCR on lymph node biopsy reveals clonal T-cell population. What is the most likely complication?", "options": ["Drug reaction with eosinophilia and systemic symptoms", "EBV-associated lymphoproliferative disorder", "Macrophage activation syndrome", "Secondary hemophagocytic lymphohistiocytosis", "TNF inhibitor-induced lymphoma"], "answer": "E", "answer_index": 4, "explanation": "TNF inhibitors like etanercept increase risk of T-cell lymphomas, especially with clonal populations on biopsy, beyond viral associations. EBV-LPD is B-cell predominant. MAS and HLH are cytokine-driven without clonality.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question presents a classic board-exam scenario: a patient on an immunosuppressant (TNF inhibitor) presenting with systemic symptoms and lymphadenopathy. The critical discriminator is the biopsy finding of a 'clonal T-cell population.' \\n\\n1. **Clonality** indicates malignancy, effectively ruling out reactive or cytokine-driven processes like DRESS (A), Macrophage Activation Syndrome (C), and Secondary HLH (D), which are characterized by polyclonal proliferation.\\n2. **Cell Type**: While EBV-associated lymphoproliferative disorders (LPD) are a known complication of immunosuppression, they are predominantly B-cell in origin. The specification of a T-cell clone makes Option B less likely than a primary T-cell malignancy.\\n3. **Etiology**: TNF inhibitors have a known association (Black Box warning) with the development of lymphomas, including T-cell lymphomas (e.g., Hepatosplenic T-cell lymphoma, though that specific subtype usually lacks lymphadenopathy, other T-cell lymphomas do present with nodes). \\n\\nOption E is the best answer as it captures both the malignant nature (Lymphoma vs. LPD/Reaction) and the T-cell lineage associated with the drug class risk. The item is logically valid and relies on standard medical heuristics.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question presents a classic board-exam scenario: a patient on an immunosuppressant (TNF inhibitor) presenting with systemic symptoms and lymphadenopathy. The critical discriminator is the biopsy finding of a 'clonal T-cell population.' \n\n1. **Clonality** indicates malignancy, effectively ruling out reactive or cytokine-driven processes like DRESS (A), Macrophage Activation Syndrome (C), and Secondary HLH (D), which are characterized by polyclonal proliferation.\n2. **Cell Type**: While EBV-associated lymphoproliferative disorders (LPD) are a known complication of immunosuppression, they are predominantly B-cell in origin. The specification of a T-cell clone makes Option B less likely than a primary T-cell malignancy.\n3. **Etiology**: TNF inhibitors have a known association (Black Box warning) with the development of lymphomas, including T-cell lymphomas (e.g., Hepatosplenic T-cell lymphoma, though that specific subtype usually lacks lymphadenopathy, other T-cell lymphomas do present with nodes). \n\nOption E is the best answer as it captures both the malignant nature (Lymphoma vs. LPD/Reaction) and the T-cell lineage associated with the drug class risk. The item is logically valid and relies on standard medical heuristics.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-010", "question": "A 68-year-old man with amyotrophic lateral sclerosis presents with progressive dysphagia and aspiration. Videofluoroscopy shows pharyngeal weakness. Non-invasive ventilation is in use. What is the most appropriate intervention?", "options": ["Percutaneous endoscopic gastrostomy placement", "Botulinum toxin injection into cricopharyngeus", "Tracheostomy for airway protection", "Speech therapy with swallowing exercises", "Pharmacologic enhancement with edrophonium"], "answer": "B", "answer_index": 1, "explanation": "In ALS with cricopharyngeal dysfunction causing dysphagia, botulinum toxin relaxes the muscle to improve swallowing, a targeted approach before invasive feeding. PEG is for nutrition but not dysphagia mechanism. Tracheostomy addresses ventilation, not swallowing.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: K (Miskeyed). Verdict: Miskeyed; Option A is the correct best answer. The clinical vignette describes a patient with ALS, progressive dysphagia, aspiration, and 'pharyngeal weakness.' The standard of care (AAN guidelines) for ALS patients with dysphagia and aspiration risk is the placement of a gastrostomy tube (Option A) to ensure safe nutrition and hydration. The keyed answer (Option B, Botulinum toxin) is used for cricopharyngeal spasm/hypertonicity, not 'pharyngeal weakness.' In the presence of pharyngeal weakness (propulsive failure), relaxing the UES with Botox is often ineffective and can worsen aspiration. Furthermore, even if cricopharyngeal dysfunction were present, PEG remains the primary intervention for the clinical problem of aspiration/dysphagia in ALS. The item is medically inaccurate as keyed because it prioritizes a niche, potentially contraindicated procedure over the standard of care.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: K (Miskeyed). Verdict: Miskeyed; Option A is the correct best answer. The clinical vignette describes a patient with ALS, progressive dysphagia, aspiration, and 'pharyngeal weakness.' The standard of care (AAN guidelines) for ALS patients with dysphagia and aspiration risk is the placement of a gastrostomy tube (Option A) to ensure safe nutrition and hydration. The keyed answer (Option B, Botulinum toxin) is used for cricopharyngeal spasm/hypertonicity, not 'pharyngeal weakness.' In the presence of pharyngeal weakness (propulsive failure), relaxing the UES with Botox is often ineffective and can worsen aspiration. Furthermore, even if cricopharyngeal dysfunction were present, PEG remains the primary intervention for the clinical problem of aspiration/dysphagia in ALS. The item is medically inaccurate as keyed because it prioritizes a niche, potentially contraindicated procedure over the standard of care.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}]